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d A paucity of literature exists to direct
physicians in the prescribing of systemic
therapies for children with refractory
atopic dermatitis.
d There is wide variation in the prescribing
practice of systemic immunomodulators
for pediatric atopic dermatitis.
d There is a need for comparative
effectiveness studies of commonly used
immunomodulators and investigation of
new biologic agents.Atopic dermatitis (AD) af-
fects nearly 20% of children
in the United States, Europe,
and Japan.1 While the major-
ity of pediatric patients can
be treated with topical ther-
apy alone, a small subset
with refractory or severe AD
requires systemic immuno-
modulatory therapy with
medications such as cyclo-
sporine (CSA), methotrexate
(MTX), mycophenolate mo-
fetil (MMF), and azathioprine
(AZA).
The European TREatment
of severe Atopic eczema in
children Taskforce (TREAT) survey confirmed wide
variation in prescribing practice of systemic immu-
nomodulators across 8 European countries.2 In 2014,
the Pediatric Dermatology Research Alliance
(PeDRA) launched the TREAT US&CANADA survey
in collaboration with the European TREAT team: (i)
to produce data on the current systemic agent
prescribing practices of pediatric dermatologists for
severe AD in the United States and Canada; (ii) to
investigate factors influencing the use of specific
systemic agents; and (iii) to inform the design of
future intervention studies.METHODS
The TREAT US&CANADA survey team devel-
oped an anonymous, online multiple-response
survey to gather information on demographics,
clinical practice data, and systemic agent selection,
as well as factors impacting systemic medication use
for refractory pediatric AD. The survey was modeled
after the European TREAT survey and was exten-
sively piloted among PeDRA members before going
live.
From September to December 2014, the survey
was distributed among select members (n = 319) of
the Society for Pediatric Dermatology. Unique,
anonymized survey links were delivered through
email and staggered reminder emails were
sent. Responders who did not prescribe systemicimmunomodulating drugs
were directed to the end of
the survey, while those who
did were presented with a
clinical scenario of an adoles-
cent patient who had failed
treatment with potent topical
corticosteroids, antihista-
mines, and phototherapy.
Participating clinicians were
asked to record their first-,
second-, and third-line
systemic drugs of choice.
Preferred dosing regimens,
including initiating and
maximal doses, length of
treatment, and discontinua-tion regimens were also queried. Use of treatment
guidelines to direct systemic treatment in severe
pediatric AD was assessed, and perceived barriers to
the use of systemic agents were recorded.RESULTS
Study population
A total of 319 invitation emails were sent to
Society for Pediatric Dermatology members.
Twenty-seven failed emails and two ineligible
participants (ie, not practicing in the United States
or Canada) were identified, leaving 290 potential
respondents. The survey was completed by 133
members (45.9%) of whom 115 (86.5%) used
systemic treatment for severe pediatric AD.
Demographic characteristics of the participants are
summarized in Table I. Of the respondents, the
majority (74.4%) were dermatologists with Pediatric
Dermatology Board certification. The majority
(66.4%) of the cohort practiced in a pediatric
dermatology setting, while 34.6% treated both
children and adults.Systemic agents and dosing schedules
The first-line systemic agents of choice were CSA
(45.2%) and MTX (29.6%). The most commonly
chosen second-line agents were MTX (31.3%) and
MMF (30.4%). AZA was the most commonly used
third-line agent (33.0%) followed by MMF (24.3%). A
Table I. Demographic characteristics of
participants
Characteristic n (%)
Sex
Female 90 (67.7)
Male 43 (32.3)
Age (years)
31-40 50 (37.6)
41-50 40 (30.1)
51-60 24 (18.0)
[60 19 (14.3)
Country of work
United States 115 (86.5)
Canada 18 (13.5)
Primary specialty
Board Certified Dermatologist with Pediatric
Dermatology Board Certification
99 (74.4)
Board Certified Dermatologist without 21 (15.8)
Abbreviations used:
AD: atopic dermatitis
AZA: azathioprine
CSA: cyclosporine
MTX: methotrexate
MMF: mycophenolate mofetil
PeDRA: Pediatric Dermatology Research
Alliance
RCT: randomized controlled trial
SCORAD: SCORing Atopic Dermatits
TREAT: TREatment of severe Atopic eczema in
children Taskforce
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Table II. Detailed dosing schedules including
initiation and maximum dose of each drug, length
of treatment, and discontinuation regimens of
respondents are provided in Table III.Pediatric Dermatology Certification
Pediatrician but not Dermatology
Board Certification
9 (6.8)
Other 4 (3.0)
Practicing location
University teaching hospital/clinic 94 (70.7)
Single-specialty group practice 17 (12.8)
Multi-specialty group practice 10 (7.5)
Solo community based practice 7 (5.3)
Integrate Health Maintenance Organization 5 (3.8)
Caseload
Pediatrics only 87 (65.4)
Pediatrics and adults 46 (34.6)
Years of experiencePractice arrangement
Nearly 63% of the physicians had facilities
available for inpatient care, and 8.7% had topical
treatment facilities for children as outpatients or
within a day treatment center. Approximately
half (48.7%) had access to nursing support for
patient/caregiver AD education, while only 13.0%
had dedicated AD education programs and schools
for patients, caregivers, or both. Drug monitoring
clinics for children on systemic therapies were
available to 14.8% of physicians.0-4 years 29 (21.8)
5-10 years 30 (22.6)
11-20 years 37 (27.8)
[20 years 37 (27.8)Factors discouraging the use of systemic
agents
Elements discouraging the use of systemic agents
were assessed in the survey (Table IV). Side-effect
profiles (82.6%) and risk for long-term organ toxicity
(81.7%) were factors that discouraged the use of
these agents. A large number of respondents (65.2%)
were discouraged by concerns expressed by patients
and their families. Approximately half (49.6%) did
not use AD guidelines or protocols to direct their
prescription of systemic treatments.DISCUSSION
With a response rate of 45.9%, our study is likely a
true representation of practice patterns among
providers utilizing systemic therapy for children
with severe AD in North America. Limitations of the
study include a small Canadian sample of 18
practitioners, preventing intercountry comparison
of clinical practice. Due to the survey methodology,
we did not query doctors about the sequence of
prescribing systemic medications or use of
combination systemic therapy. Because chart auditswere not required from respondents, recall bias is
another potential limitation.
Our study reveals great variation in prescribing
practices among North American physicians pre-
scribing systemic agents for pediatric AD. The results
differ from those seen in the European TREAT study,
which queried 343 individuals from 8 different
European countries, and found CSA to be the most
commonly used first-line agent (43.0%), followed by
oral corticosteroids (30.7%) and AZA (21.7%). CSA
was the most commonly used second-line agent
(33.6%) andMTX the most commonly used third-line
systemic treatment (26.2%). While both our study
and its European counterpart found CSA to be the
most commonly prescribed first-line agent, the use of
MTX differed greatly. MTX was most often a
third-line agent in Europe but commonly used as
first-line therapy in the United States and Canada. An
Table II. Treatment of choice
Drug selection, n (%) Cyclosporine Methotrexate Mycophenolate mofetil Azathioprine Oral corticosteriods Other
First Line 52 (45.2) 34 (29.6) 15 (13.0) 8 (7.0) 6 (5.2) 0 (0.0)
Second Line 21 (18.3) 36 (31.3) 35 (30.4) 23 (20.0) 0 (0.0) 0 (0.0)
Third Line 20 (17.4) 22 (19.1) 28 (24.3) 38 (33.0) 2 (1.7) 5 (4.3)*
*Includes dapsone, intravenous immunoglobulin.
Table III. Dosing schedules
Initial dose (%) Maximum dose (%)
Average duration
of treatment (%)
Maximum duration
of treatment (%)
Regimen to discontinue
treatment (%)
Azathiprine 2 mg/kg/day
(55.1%)
3 mg/kg/day
(70.0%)
4-12 months
(60.9%)
[12 months (73.9%) Taper dose over
1 month (52.2%)
Cyclosporine 3-5 mg/kg/day
(53.8%)
3-5 mg/kg/day
(71.0%)
4-12 months
(65.6%)
4-12 months (62.4%) Taper dose over
1 month (48.4%)
Methotrexate 300 mcg/kg/
week (26.1%)
[400mcg/kg/
week (47.8%)
4-12 months
(70.7%)
[12 months (78.3%) Taper dose over
1 month (34.8%)
Mycophenolate
mofetil
10 mg/kg/day
(39.7%)
[20 mg/kg/day
(41.0%)
4-12 months
(66.7%)
[12 months (64.1%) Taper dose over
1 month (51.3%)
Oral
corticosteroids
1 mg/kg/day
(87.0%)
2 mg/kg/day
(75.0%)
2-4 weeks
(62.5%)
1-2 months (50.0%) Variable* among
n = 8
*Includes taper dose over 1 month, half dose every 2 weeks, discontinue without a taper, taper dose over 1 week, and 3-4 week taper.
Table IV. Factors that discouraged the use of systemic agents
Strongly agree, % (n) Agree, % (n) Neutral, % (n) Disagree, % (n) Strongly disagree, % (n)
Perceived risk of long-term
organ toxicity
25.2% (29) 56.5% (65) 13.0% (15) 3.5% (4) 1.7% (2)
Side-effect profile 23.5% (27) 59.1% (68) 10.4% (12) 4.3% (5) 2.6% (3)
Concerns expressed by
patient/family
11.3% (13) 53.9% (62) 22.6% (26) 9.6% (11) 2.6% (3)
Need for blood monitoring 5.2% (6) 27.8% (32) 30.4% (35) 25.2% (29) 11.3% (13)
Lack of guidelines 4.3% (5) 29.6% (34) 30.4% (35) 25.2% (29) 10.4% (12)
Lack of prescribing indication
for atopic dermatitis in children
2.6% (3) 25.2% (29) 33.9% (39) 26.1% (30) 12.2% (14)
Lack of personal experience 2.6% (3) 10.4% (12) 21.7% (25) 41.7% (48) 23.5% (27)
Financial constraints 1.7% (2) 19.1% (22) 30.4% (35) 33.0% (38) 15.7% (18)
Colleagues with more experience
in the use of systemic agents
to whom I would refer the child
0.0% (0) 4.3% (5) 15.7% (18) 48.7% (56) 31.3% (36)
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European TREAT study was completed shortly after
publication of a randomized controlled trial (RCT)
comparing MTX with AZA, which supported a role
for MTX in themanagement of adults with AD.3 Since
this publication, MTX use in Europe may have
increased.
There is only one published RCT looking at
systemic treatments for severe AD in children. El
Khalawany et al compared CSA and MTX in 40
children with severe AD. At week 12, patients in the
MTX group had a mean (6standard deviation [SD])
absolute reduction in SCORing Atopic Dermatits(SCORAD) of 26.25 6 7.03, compared with
25.02 6 8.21 in the CSA group (P = .93). Both drugs
were associated with minor adverse effects, none of
which necessitated changing the treatment regimen.
The authors concluded that, when used in low doses,
both drugs are clinically effective, relatively safe,
and well tolerated.4 This study was statistically
underpowered and had a relatively short treatment
period of 12 weeks. Furthermore, a fixed low dose of
MTX was used in the study, inconsistent with usual
clinical practice. The onset of benefit from both
drugs appeared to be similar, which also does not
reflect clinical experience (CSA has the most
J AM ACAD DERMATOL
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immunomodulating agents).5,6
To date, no systemic therapies are approved by
the Food and Drug Administration for the treatment
of AD in children. CSA is approved for the treatment
of AD in adults in various countries and children over
16 years of age in Germany and France.7 Additional
RCTs are needed to determine the optimal dosing
and duration of therapy for pediatric patients with
AD and to compare the efficacy of different systemic
agents. A national RCT comparing cyclosporine and
methotrexate is currently underway in the United
Kingdom (TREAT, trial registration 15837754).
Comparative studies of commonly used therapies
and novel systemic agents, such as biologics, should
also be pursued.
Our data displays a high rate of concern about
side-effect profiles and risks for long-term toxicity
with presently used systemic agents. There is a
clinical need for development and testing of new
systemic agents for pediatric AD.REFERENCES
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